疫苗接种前时代带状疱疹的流行病学:为评估西班牙疫苗接种规划影响建立基线
该研究利用西班牙国家卫生系统医院出院记录数据库,回顾性分析1998至2018年全部带状疱疹相关住院病例共65,401例,年均住院率为6.75/10万人口,住院率呈上升趋势,男性及65岁以上人群更高。白血病/淋巴瘤和实体恶性肿瘤与再入院风险升高相关,白血病/淋巴瘤、实体恶性肿瘤和HIV感染与死亡风险升高相关。作者认为死亡或再入院风险较高的患者群体属于西班牙卫生部当前疫苗接种建议的优先人群。
要点
- 1998至2018年西班牙带状疱疹相关住院共65,401例,年均住院率6.75/10万人口。
- 带状疱疹住院率在研究期间呈上升趋势,男性及65岁以上人群更高。
- 白血病/淋巴瘤和实体恶性肿瘤与再入院风险升高相关,白血病/淋巴瘤、实体恶性肿瘤和HIV感染与死亡风险升高相关。
核心结论
- 在因带状疱疹住院的所有患者中,死亡或再入院风险较高的患者群体属于西班牙卫生部当前疫苗接种建议所优先覆盖的人群。
- 本研究提供了带状疱疹临床方面的相关信息,并为未来评估疫苗接种政策建立了基础。
研究设计与样本
- 回顾性研究,使用西班牙国家卫生系统医院出院记录数据库,纳入1998至2018年全部带状疱疹相关住院病例。
主要发现
- 带状疱疹相关住院共65,401例,对应年均住院率为6.75/10万人口。
- 研究期间带状疱疹住院呈上升趋势。
- 住院率在男性和年龄较大人群中更高,尤其是65岁以上人群。
- 再入院风险较高的合并症为白血病/淋巴瘤(RR 2.4;95% CI:2.3-2.6)和实体恶性肿瘤(RR 2.2;95% CI:2.1-2.4)。
- 死亡风险较高的合并症为白血病/淋巴瘤(RR 2.9;95% CI:2.7-3.2)、实体恶性肿瘤(RR 2.9;95% CI:2.7-3.1)和HIV感染(RR 2.2;95% CI:1.8-2.7)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BackgroundHerpes zoster (HZ) affects 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age and the presence of immunocompromising conditions. In Spain, vaccination guidelines were recently updated to include the recommendation of the new recombinant zoster vaccine (RZV) for certain risk groups.AimTo describe the epidemiology of HZ-related hospitalisations in Spain in order to prioritise vaccination recommendations and define a baseline to monitor the effectiveness of vaccination policies.MethodsRetrospective study using the National Health System's Hospital Discharge Records Database, including all HZ-related hospitalisations from 1998 to 2018.ResultsThe 65,401 HZ-related hospitalisations, corresponded to an annual mean hospitalisation rate of 6.75 per 100,000 population. There was an increasing trend of HZ hospitalisations over the study period. This rate was higher in males and older age groups, particularly over 65 years. Comorbidities with higher risk of readmission were leukaemia/lymphoma (RR 2.4; 95% CI: 2.3-2.6) and solid malignant neoplasm (RR 2.2; 95% CI: 2.1-2.4). Comorbidities associated with higher risk of mortality were leukaemia/lymphoma (RR 2.9; 95% CI: 2.7-3.2), solid malignant neoplasm (RR 2.9; 95% CI: 2.7-3.1) and HIV infection (RR 2.2; 95% CI: 1.8-2.7).ConclusionOf all patients hospitalised with HZ, those with greater risk of mortality or readmission belonged to the groups prioritised by the current vaccination recommendations of the Spanish Ministry of Health. Our study provided relevant information on clinical aspects of HZ and established the base for future assessments of vaccination policies.
引用
- Risco Risco C, Herrador Z, Lopez-Perea N, et al. Epidemiology of Herpes Zoster in the pre-vaccination era: establishing the baseline for vaccination programme's impact in Spain. Euro Surveill. 2023. PMID: 36820639. doi:10.2807/1560-7917.ES.2023.28.8.2200390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。